An Open-Label Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer

Trial Profile

An Open-Label Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 04 May 2017

At a glance

  • Drugs Rovalpituzumab tesirine (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Sponsors AbbVie
  • Most Recent Events

    • 28 Apr 2017 Planned End Date changed from 1 Dec 2020 to 25 Mar 2020.
    • 28 Apr 2017 Planned initiation date changed from 31 Mar 2017 to 30 Apr 2017.
    • 24 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top